Trials / Active Not Recruiting
Active Not RecruitingNCT06612697
Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone
Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 262 (actual)
- Sponsor
- Taichung Veterans General Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Nasopharyngeal carcinoma (NPC) is a malignant tumor primarily originating in the nasopharynx, commonly found in populations in southern China, certain regions of Asia, and North Africa. The main treatment for NPC is primarily radiotherapy, with some patients receiving combined chemotherapy. Early-stage NPC patients can achieve adequate tumor control with radiation therapy alone. Various studies report that the 5-year survival rate for very early-stage NPC exceeds 90%. However, some stage I patients experience local recurrence or distant metastasis after treatment, indicating treatment failure. This study aims to retrospectively analyze the factors contributing to treatment failure and prognostic factors in this group of early-stage NPC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Radiology | A retrospective analysis was conducted using systematic records from the Department of Radiation Oncology at our hospital. The study included patients diagnosed with nasopharyngeal carcinoma through endoscopic pathological reports from January 1, 1984, to December 31, 2022. Eligible patients had baseline imaging (CT or MRI) prior to treatment, received definitive radiotherapy at our institution, and were followed up long-term with complete medical records. |
Timeline
- Start date
- 2023-10-02
- Primary completion
- 2024-07-01
- Completion
- 2025-09-01
- First posted
- 2024-09-25
- Last updated
- 2024-09-25
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT06612697. Inclusion in this directory is not an endorsement.